Please add the Sequence Listing attached hereto as Appendix 1 to the end of the specification.

Attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attached page is captioned ``**Version with markings to show changes made**``.

REMARKS

In the November 22, 2001, Communication the Examiner asserted that Applicants` response to a previous Communication dated July 10, 2000 was not fully responsive, because Applicants failed to comply with the requirements of 37 C.F.R. 1.821 through 1.825.

In response, Applicants submit herewith a copy of the Notice to Comply; and the Sequence Listing on a paper and computer readable format in compliance with the requirements of 1.821 through 1.825. The computer readable form containing the nucleic acid and/or amino acid sequences as required by 37 C.F.R. 1.821(f) contains the same information which is submitted as Sequence Listing, the Sequence Listing complies with the requirements of 37 C.F.R. 1.824 and does not contain any new matter. Further, Applicants have hereinabove amended the Specification in order to conform the Specification to the Sequence I.D. Listing. Thus, Applicants` Specification is in compliance with 37 C.F.R. 1.821 through 1.825. Therefore, Applicants respectfully request the Examiner to reconsider and withdraw the objection.

No fee is due for filing this Amendment. However, if any fee is required, the undersigned Attorney hereby authorizes the United States Patent and Trademark Office to charge such fee to Deposit Account No. 05-0649.

Respectfully submitted,

Mark S. Cohen
Attorney for Applicant(s)
Registration No. 42,425

Dated: May 17, 2001

Eitan, Pearl, Latzer & Cohen-Zedek
One Crystal Park, Suite 210, 2011 Crystal Drive
Arlington, VA, USA 22202-3709
Telephone: (703) 486-1177
Fax: (703) 486-0800

Version with markings to show changes made

In the specification:

Paragraph beginning at page 7, line 31 has been amended as follows:

Fig. 1. Schematic presentation of AdRSVpHyde structure. The 2664 bp inserted fragment contains a 1467 bp full-length pHyde cDNA gene (SEQ ID NO: [1]3) and 1166 bp 3' untranslated downstream region. The complete sequence of AdRSVpHyde is set forth in Figure 10[,]. Specifically, the nucleic acid sequence of region A in Figure 1 is set forth in Figure 10 Region A (SEQ ID NO: 5) and the nucleic acid sequence of region B in Figure 1 is set forth in Figure 10 at Region B (SEQ ID NO: 6).

Paragraph beginning at page 9, line 25 has been amended as follows:

Figure 10. The complete sequence of AdRSVpHyde. Region A of AdRSVpHyde (SEQ ID NO: 5). Region B of AdRSVpHyde (SEQ ID NO: 6).

Paragraph beginning at page 90, line 13 has been amended as follows:

Construction of AdRSVpHyde: A rat pHyde cDNA gene was isolated as described in U.S. Serial No: 09/302,457. After digestion with EcoRI, a 2.6 kb fragment which contains the 1467 bp full-length coding sequence of pHyde cDNA was subcloned under the control of a truncated RSV promoter (395 bp) into an E1/E3 deleted adenoviral shuttle vector. The resultant adenoviral shuttle vector was cotransfected into 293 cells with pJM17, an adenoviral type 5 genome plasmid, by calcium phosphate method. Individual plaques were screened for recombinant AdRSVpHyde by PCR using specific primers for both the RSV promoter and pHyde cDNA sequences. Single viral clones were propagated in 293 cells. The culture medium of the 293 cells showing the completed cytopathic effect (CPE) was collected, and the adenovirus was purified and concentrated by twice CsC12 gradient untracentrifugation. The viral titration and transduction were performed as previously described. The schematic

diagram of AdRSVpHyde was illustrated in Fig. 1. The sequence of AdRSVpHyde is set forth in Figure 10 (SEQ ID NO: 5 and SEQ ID NO: 6).